Table 1.
Baseline characteristics of participants
| Clinical characteristics | Placebo (n = 8) | Elinzanetant 40 mg (n = 8) | Elinzanetant 80 mg (n = 9) | Elinzanetant 120 mg (n = 8) | P | |
|---|---|---|---|---|---|---|
| Age, y | Median | 32.0 | 35.5 | 30.0 | 29.5 | .91 |
| IQR | 9.00 | 4.75 | 11.00 | 11.75 | ||
| Sex, n (%) | Female | 8 (100) | 8 (100) | 9 (100) | 8 (100) | – |
| Race, n (%) | White | 7 (87.5) | 7 (87.5) | 8 (88.9) | 8 (100) | – |
| Black or African American | 1 (12.5) | 1 (12.5) | 1 (11.1) | 0 | – | |
| Weight, kg | Median | 69.70 | 63.65 | 73.10 | 59.75 | .68 |
| IQR | 12.85 | 10.45 | 23.40 | 17.68 | ||
| BMI, kg/m2 | Median | 25.90 | 24.65 | 29.20 | 22.95 | .25 |
| IQR | 4.30 | 2.53 | 2.60 | 5.05 | ||
| Smoker, n (%) | Nonsmoker | 8 (100) | 8 (100) | 9 (100) | 8 (100) | – |
Comparison is made using Kruskal-Wallis with post hoc Dunn multiple comparison test.
Abbreviations: BMI, body mass index; IQR, interquartile range.